GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Float Percentage Of Total Shares Outstanding

Celldex Therapeutics (Celldex Therapeutics) Float Percentage Of Total Shares Outstanding : 86.97% (As of Apr. 28, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celldex Therapeutics's float shares is 57.32 Mil. Celldex Therapeutics's total shares outstanding is 65.91 Mil. Celldex Therapeutics's float percentage of total shares outstanding is 86.97%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celldex Therapeutics's Insider Ownership is 10.14%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celldex Therapeutics's Institutional Ownership is 63.34%.


Celldex Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Celldex Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=57.32/65.91
=86.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celldex Therapeutics (Celldex Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Executives
Garry Arthur Neil director 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler officer: Sen. VP & Ch Scientific Off. 30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh officer: SVP of Corp. Affairs & Admin. C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young officer: SVP, Chief Medical Officer 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci director, officer: President and CEO 66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright officer: Sr. VP & CCO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin officer: SVP and CFO C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi officer: SVP of of Regulatory Affairs C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley officer: SVP, Chief Product Dev Officer C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez officer: SVP & General Counsel C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114

Celldex Therapeutics (Celldex Therapeutics) Headlines

From GuruFocus

Celldex to Participate in Upcoming November Investor Conferences

By Value_Insider Value_Insider 11-10-2022